X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs LUPIN LTD - Comparison Results

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA LUPIN LTD PLETHICO PHARMA/
LUPIN LTD
 
P/E (TTM) x -1.1 22.9 - View Chart
P/BV x 0.0 3.1 0.5% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 PLETHICO PHARMA   LUPIN LTD
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
LUPIN LTD
Mar-17
PLETHICO PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs3951,750 22.6%   
Low Rs311,384 2.3%   
Sales per share (Unadj.) Rs604.4387.4 156.0%  
Earnings per share (Unadj.) Rs32.556.6 57.3%  
Cash flow per share (Unadj.) Rs51.376.8 66.8%  
Dividends per share (Unadj.) Rs07.50 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs473.6298.9 158.4%  
Shares outstanding (eoy) m34.08451.58 7.5%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x0.44.0 8.7%   
Avg P/E ratio x6.627.7 23.7%  
P/CF ratio (eoy) x4.220.4 20.4%  
Price / Book Value ratio x0.55.2 8.6%  
Dividend payout %013.2 0.0%   
Avg Mkt Cap Rs m7,262707,513 1.0%   
No. of employees `000NA16.8 0.0%   
Total wages/salary Rs m1,59628,495 5.6%   
Avg. sales/employee Rs ThNM10,418.3-  
Avg. wages/employee Rs ThNM1,697.0-  
Avg. net profit/employee Rs ThNM1,523.0-  
INCOME DATA
Net Sales Rs m20,598174,943 11.8%  
Other income Rs m3861,065 36.3%   
Total revenues Rs m20,984176,008 11.9%   
Gross profit Rs m2,81844,931 6.3%  
Depreciation Rs m6429,122 7.0%   
Interest Rs m1,5931,525 104.5%   
Profit before tax Rs m96935,349 2.7%   
Minority Interest Rs m0-72 0.0%   
Prior Period Items Rs m083 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1389,785 -1.4%   
Profit after tax Rs m1,10725,575 4.3%  
Gross profit margin %13.725.7 53.3%  
Effective tax rate %-14.327.7 -51.6%   
Net profit margin %5.414.6 36.8%  
BALANCE SHEET DATA
Current assets Rs m18,877119,542 15.8%   
Current liabilities Rs m11,89661,206 19.4%   
Net working cap to sales %33.933.3 101.6%  
Current ratio x1.62.0 81.2%  
Inventory Days Days3676 47.3%  
Debtors Days Days19890 220.1%  
Net fixed assets Rs m9,861131,660 7.5%   
Share capital Rs m341903 37.7%   
"Free" reserves Rs m12,331134,073 9.2%   
Net worth Rs m16,139134,976 12.0%   
Long term debt Rs m4,70656,478 8.3%   
Total assets Rs m33,146266,073 12.5%  
Interest coverage x1.624.2 6.7%   
Debt to equity ratio x0.30.4 69.7%  
Sales to assets ratio x0.60.7 94.5%   
Return on assets %8.110.2 80.0%  
Return on equity %6.918.9 36.2%  
Return on capital %12.319.3 63.8%  
Exports to sales %21.40-   
Imports to sales %15.20-   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,136NA-   
Fx inflow Rs m4,40281,885 5.4%   
Fx outflow Rs m3,18421,506 14.8%   
Net fx Rs m1,21960,378 2.0%   
CASH FLOW
From Operations Rs m2,43741,148 5.9%  
From Investments Rs m-6,265-25,287 24.8%  
From Financial Activity Rs m2,4904,332 57.5%  
Net Cashflow Rs m-1,33720,193 -6.6%  

Share Holding

Indian Promoters % 82.7 46.6 177.5%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 4.3 11.3 38.1%  
FIIs % 5.5 31.9 17.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 10.1 74.3%  
Shareholders   10,665 98,259 10.9%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  ELDER PHARMA  SANOFI INDIA  DR. DATSONS LABS  

Compare PLETHICO PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty at Record Close Yet Again; IT & Realty Stocks Rally(Closing)

Indian share markets extended rally in the final hour of the trade, hitting fresh record highs while the Bank nifty touched 27,000 level for the first time. At the closing bell.

Related Views on News

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 8-QTR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS